OKYO Pharma logo

OKYO - OKYO Pharma News Story

12.65p -2.0  -13.6%

Last Trade - 11:04am

Sector
Healthcare
Size
Small Cap
Market Cap £82.1m
Enterprise Value £82.1m
Revenue £n/a
Position in Universe 1001st / 1819

OKYO Pharma Limited - Result of AGM

Mon 2nd March, 2020 11:50am
RNS Number : 6877E
OKYO Pharma Limited
02 March 2020
 

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

OKYO Pharma Limited

("OKYO" or the "Company")

 

Result of Annual General Meeting

 

At the Annual General Meeting of the Company held at 10.00 a.m. on 2 March 2020 at the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London, EC2V 6DN, all of the resolutions were duly passed.

 

The results of the proxy voting will be available shortly on the Company's website, www.okyopharma.com.

The person who arranged for the release of this announcement was Tiziano Lazzaretti, Chief Financial Officer.

 

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

 

Enquiries:

 

OKYO Pharma Limited

Willy Simon

 

+44 (0)20 7382 8300

Shore Capital  Limited (Broker)

Antonio Bossi

David Coaten

 

+44 (0)20 7601 6100

For further information, please visit the Company's website at www.okyopharma.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGKKBBBDBKDNNK
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.